The content on this site is intended for healthcare professionals only
Prof Andreas Engert speaks to ecancer about managing Hodgkin lymphoma (HL) patients during the COVID-19 pandemic.
Prof Engert outlines considerations on selecting a first-line treatment for untreated advanced-stage HL patients during COVID-19 and specific precautions that should be considered for HL patients with a pulmonary co-morbidity or toxicity due to treatments at this time.
He discusses the difficulties of using bleomycin in light of the pandemic, suggesting that the risks of this treatment are likely to outweigh the potential benefits, particularly for high-risk patients.
Prof Engert goes on to identify patient subgroups who require specific considerations regarding treatment due to COVID-19, including relapsed / refractory patients, and gives his recommendations for how to approach their treatment.
He concludes by speaking about how the pandemic has impacted cancer care generally and stresses the need to carefully consider treatment plans for at-risk patients during this time.
This programme has been supported by an unrestricted educational grant from Takeda.
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective
SIOG 2024: Updates in medical oncology
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Multiple myeloma (A cancer arising from plasma cells)
Neo-adjuvant therapy for different cancers in the Philippines
